Who is sponsoring NCT05124275?

NCT05124275 is sponsored by Glaukos Corporation.

What drugs are being tested in NCT05124275?

Interventions in NCT05124275: Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3, Placebo Ophthalmic Topical Cream.

What condition does NCT05124275 study?

NCT05124275 studies Presbyopia.

Is NCT05124275 still recruiting?

NCT05124275 is currently completed. Last updated 1 September 2023.

Last reviewed 2023-09-01 · How we verify

NCT05124275

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia

Completed Phase 2 Last updated 1 September 2023

What this trial tests

Phase 2 trial testing Pilocarpine Ophthalmic Topical Cream, Dose 1 in Presbyopia in 123 participants. Completed in 6 September 2022.

Timeline

3 January 2022

Primary endpoint
6 September 2022

6 September 2022

Quick facts

Lead sponsor	Glaukos Corporation
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	123
Start date	3 January 2022
Primary completion	6 September 2022
Estimated completion	6 September 2022
Sites	10 locations across United States

Drugs / interventions tested

Pilocarpine Ophthalmic Topical Cream, Dose 1 — full drug profile →
Pilocarpine Ophthalmic Topical Cream, Dose 2
Pilocarpine Ophthalmic Topical Cream, Dose 3
Placebo Ophthalmic Topical Cream — full drug profile →

Conditions studied

Presbyopia — all drugs for Presbyopia →

Sponsor

Glaukos Corporation — full company profile →

Who can join

Adults 40 to 55, any sex, with Presbyopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Multicenter, Randomized, Double-Masked Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pharmacological Treatment in Presbyopia.
Grzybowski A, Ruamviboonsuk V. · · 2022 · cited 27× · PMID 35268476 · DOI 10.3390/jcm11051385

Verify or expand the search:

Other recruiting trials for Presbyopia

Currently open trials in the same condition.

NCT07444658 — Performance of Two Daily Disposable Multifocal Contact Lenses · NA · recruiting
NCT07284966 — Comfort and Vision With TOTAL30 Multifocal Lenses · recruiting
NCT07077967 — Luminous Efficiency Function V(λ)' of Patients That Underwent Pseudophakic Presbyopic Corrections With EDOF IOLs · recruiting
NCT07113210 — Quality of Life in Presbyopic Patients Who Are Treated With Qlosi · Phase 4 · recruiting
NCT06948357 — Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients · Phase 2 · recruiting

Other Glaukos Corporation trials

Trials by the same sponsor.

NCT06061718 — Travoprost Intraocular Implant in Conjunction With Cataract Surgery · Phase 3 · active not recruiting
NCT05119920 — Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease · Phase 2 · completed
NCT05127551 — Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite Vs. Competitor · NA · active not recruiting
NCT06582732 — Performance of the Travoprost Intraocular Implant · Phase 2 · completed
NCT04615403 — Study of Exchange of Travoprost Intraocular Implant · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05124275 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Glaukos Corporation
Last refreshed: 1 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05124275.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing